Showing results (261-270 of 281) with videos related to

Sort By:
Pageof 29
Cancer Treatment Reports|September 1, 1987
Phase I clinical trial of methylene dimethane sulfonateD B Smith, B W Fox, N Thatcher, et al.
Gene Therapy|September 25, 1998
Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferaseN Chinnasamy, J A Rafferty, I Hickson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patientsH Sharma, N Thatcher, J Baer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1996
An open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating FactorS Bretti, M H Gilleece, A Kamthan, et al.
The Journal of Cell Biology|April 29, 1998
An activated protein kinase C alpha gives a differentiation signal for hematopoietic progenitor cells and mimicks macrophage colony-stimulating factor-stimulated signaling eventsA Pierce, C M Heyworth, S E Nicholls, et al.
British Journal of Cancer|December 1, 1996
A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamideA Weaver, E Wrigley, A Watson, et al.
Gene|July 7, 1999
Upstream elements bestow T-cell and haemopoietic progenitor-specific activity on the granzyme B promoterB A Johnson, V A John, R Henschler, et al.
Blood|June 15, 1992
"Stem cell" origin of the hematopoietic defect in dyskeratosis congenitaJ C Marsh, A J Will, J M Hows, et al.
British Journal of Cancer|August 1, 1993
A phase I study of intravenous bryostatin 1 in patients with advanced cancerJ Prendiville, D Crowther, N Thatcher, et al.
British Journal of Haematology|June 1, 1996
Evaluation of cytogenetic conversion to Ph- haemopoiesis in long-term bone marrow culture for patients with chronic myeloid leukaemia on conventional hydroxyurea therapy, on pulse high-dose hydroxyurea and on interferon-alphaL H Coutinho, M L Brereton, A M Santos, et al.
Pageof 29